由眼未来主办的 第二届全球眼科大会（Global Ophthalmology Conference 2026） 将于 2026年3月19日 在北京 中关村展示中心 举办。 本届大会延续 "医工融合 × 科技创新 × 临床价值" 的整体定位，聚焦眼科成像、屈光与近视、创新治疗、手术技术、临床前验证等多领域趋势，呈现眼科产 业科技的前沿全景。 大会同期开放 「2026全球眼科年度奖项」申报及《全球眼科创新白皮书》联合撰写席位 ，诚邀各方团队共筑权威成果、共享国际平台。 首届眼科大会回顾 报名方式见以下链接： 奖项申报通知！第二届全球眼科大会 白皮书合作 | 《2026全球眼科创新白皮书》共建计划 大会亮点概览 首届眼科大会回顾 会场与展区 年度白皮书发布： 大会现场发布 《2026全球眼科创新白皮书》 。 奖项盛典： 颁发 "眼科创新系列大奖" ，树立行业标杆，让创新被看见。 精品展位与深度互动： 会场核心区设有 精品展位 ，为赞助商提供与全场高质量决策者面对面洽谈、产品演示与合作签约的高效平台。 创新Demo Hour： 十余家精选创新团队进行 5–10分钟 高密度路演 ，直击投资与合作需求，打造前沿技术首发阵 ...

Group 1: Market Overview - The global capital is increasingly focusing on the medical device distribution sector, with Medline Industries planning a potential IPO that could exceed a valuation of $50 billion, marking it as the largest IPO in the medical device industry by 2025 [1] - The Chinese medical device market is projected to reach a scale of 1.2 trillion yuan by 2024, with a significant acceleration towards intelligent supply chain solutions [2] - The traditional high-value consumables distribution in China remains fragmented and inefficient, with over 1.42 million companies involved, leading to long order processing times and inefficiencies [2] Group 2: Company Innovations - Jianfa Zhixin has recently listed on the ChiNext board, showcasing its innovative capabilities in reconstructing the supply chain value system [3] - The company has established a comprehensive medical supply chain hub, covering all provinces in China and serving over 3,300 medical institutions, with a focus on high-value interventional products [5] - Jianfa Zhixin's business model innovation includes a dual approach of direct sales and distribution, enhancing its service capabilities and collaboration with leading manufacturers [5] Group 3: Operational Efficiency - The company has implemented a Supply Chain Management (SPD) service model that addresses hospital management pain points, significantly improving operational efficiency [6][9] - Jianfa Zhixin has provided full-process operational services to 60 hospitals, managing over 10 billion yuan, with a notable recognition as a pilot unit for hospital logistics service standards [7] - The SPD model has demonstrated substantial improvements in resource allocation efficiency, reducing material requisition times and error rates in hospitals [9] Group 4: Digital Transformation - The company has built a robust digital supply chain management system, leveraging information technology and IoT to enhance operational efficiency and compliance [10] - Jianfa Zhixin's unique identification management technology addresses traditional coding issues, ensuring regulatory compliance and facilitating data flow from production to usage [10] Group 5: Market Potential and Capital Dynamics - The high-value medical device market in China has shown significant growth, with a compound annual growth rate of 15.79% from 2016 to 2023, providing a favorable environment for Jianfa Zhixin [12] - The capital market is experiencing a recovery, creating a conducive environment for Jianfa Zhixin's growth and valuation enhancement [15] - Analysts predict continued investment opportunities in the medical device sector, with a focus on undervalued stocks and supportive policies for innovation [18] Group 6: Strategic Outlook - The company's fundraising efforts will focus on upgrading information systems and enhancing centralized operations for medical consumables, reflecting a deep understanding of industry trends [19] - As management and business models continue to evolve, Jianfa Zhixin is expected to play a leading role in industry consolidation, with the capital market reassessing the value of leading companies in the medical device distribution sector [19]